FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765431857> ?p ?o ?g. }

• W2765431857 endingPage "303" @default.
• W2765431857 startingPage "293" @default.
• W2765431857 abstract "Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH).To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies.Thirty-three patients who received full induction GEM/DOCE since 2011, per the protocol adapted from U. Iowa, were identified and characterized. Multivariable logistic regression was used to determine factors associated with recurrence. Cox proportional hazard models evaluated risk factors for disease-free survival (DFS) and high-grade recurrence-free survival (HG-RFS).There were no serious adverse effects of therapy. Across all patients, median follow-up time was 18.6 months with a median DFS of 6.5 months, 42% 1-year, and 24% 2-year DFS. Median HG-RFS was 17.1 months with 56% 1-year and 42% 2-year HG-RFS. Among patients initially presenting with HG-NMIBC, 46% (13/28) had HG recurrence. BCG unresponsive/relapsing patients (N = 25) displayed 49% 1-year HG-RFS and 34% 2-year HG-RFS. In total, there were 5 LG and 16 HG recurrences, with 5 progressions and 8 cystectomies among these.GEM/DOCE is a well-tolerated therapy that deserves further study as an alternative to immediate RC for highly selected patients with HG-NMIBC. BCG naïve patients responded more effectively than BCG unresponsive/relapsing patients. As anticipated, GEM/DOCE efficacy was improved for HG only patients." @default.
• W2765431857 created "2017-11-10" @default.
• W2765431857 creator A5002819180 @default.
• W2765431857 creator A5002892743 @default.
• W2765431857 creator A5006746061 @default.
• W2765431857 creator A5026155372 @default.
• W2765431857 creator A5029009031 @default.
• W2765431857 creator A5031824644 @default.
• W2765431857 creator A5046069081 @default.
• W2765431857 creator A5059664401 @default.
• W2765431857 creator A5077350606 @default.
• W2765431857 date "2017-10-27" @default.
• W2765431857 modified "2023-10-09" @default.
• W2765431857 title "Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer" @default.
• W2765431857 cites W1538488400 @default.
• W2765431857 cites W162912078 @default.
• W2765431857 cites W172279490 @default.
• W2765431857 cites W1863833365 @default.
• W2765431857 cites W1949498553 @default.
• W2765431857 cites W1974039662 @default.
• W2765431857 cites W1977825672 @default.
• W2765431857 cites W1981394175 @default.
• W2765431857 cites W1987806240 @default.
• W2765431857 cites W1993942185 @default.
• W2765431857 cites W2018777508 @default.
• W2765431857 cites W2020921800 @default.
• W2765431857 cites W2029780593 @default.
• W2765431857 cites W2042179480 @default.
• W2765431857 cites W2045846742 @default.
• W2765431857 cites W2067183364 @default.
• W2765431857 cites W2076954194 @default.
• W2765431857 cites W2124017956 @default.
• W2765431857 cites W2138925237 @default.
• W2765431857 cites W2152106693 @default.
• W2765431857 cites W2152206210 @default.
• W2765431857 cites W2153987453 @default.
• W2765431857 cites W2155829623 @default.
• W2765431857 cites W2160098218 @default.
• W2765431857 cites W2270022169 @default.
• W2765431857 cites W2293986631 @default.
• W2765431857 cites W2343997144 @default.
• W2765431857 cites W2414199713 @default.
• W2765431857 cites W2505479500 @default.
• W2765431857 cites W2512402033 @default.
• W2765431857 cites W2550250608 @default.
• W2765431857 cites W2593384642 @default.
• W2765431857 cites W2916183155 @default.
• W2765431857 cites W4211053712 @default.
• W2765431857 cites W4236503619 @default.
• W2765431857 cites W594984707 @default.
• W2765431857 doi "https://doi.org/10.3233/blc-170126" @default.
• W2765431857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5676758" @default.
• W2765431857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29152553" @default.
• W2765431857 hasPublicationYear "2017" @default.
• W2765431857 type Work @default.
• W2765431857 sameAs 2765431857 @default.
• W2765431857 citedByCount "51" @default.
• W2765431857 countsByYear W27654318572018 @default.
• W2765431857 countsByYear W27654318572019 @default.
• W2765431857 countsByYear W27654318572020 @default.
• W2765431857 countsByYear W27654318572021 @default.
• W2765431857 countsByYear W27654318572022 @default.
• W2765431857 countsByYear W27654318572023 @default.
• W2765431857 crossrefType "journal-article" @default.
• W2765431857 hasAuthorship W2765431857A5002819180 @default.
• W2765431857 hasAuthorship W2765431857A5002892743 @default.
• W2765431857 hasAuthorship W2765431857A5006746061 @default.
• W2765431857 hasAuthorship W2765431857A5026155372 @default.
• W2765431857 hasAuthorship W2765431857A5029009031 @default.
• W2765431857 hasAuthorship W2765431857A5031824644 @default.
• W2765431857 hasAuthorship W2765431857A5046069081 @default.
• W2765431857 hasAuthorship W2765431857A5059664401 @default.
• W2765431857 hasAuthorship W2765431857A5077350606 @default.
• W2765431857 hasBestOaLocation W27654318572 @default.
• W2765431857 hasConcept C121608353 @default.
• W2765431857 hasConcept C126322002 @default.
• W2765431857 hasConcept C126894567 @default.
• W2765431857 hasConcept C141071460 @default.
• W2765431857 hasConcept C143998085 @default.
• W2765431857 hasConcept C197934379 @default.
• W2765431857 hasConcept C207103383 @default.
• W2765431857 hasConcept C2775910329 @default.
• W2765431857 hasConcept C2780258809 @default.
• W2765431857 hasConcept C2780352672 @default.
• W2765431857 hasConcept C2781190966 @default.
• W2765431857 hasConcept C2781413609 @default.
• W2765431857 hasConcept C44249647 @default.
• W2765431857 hasConcept C50382708 @default.
• W2765431857 hasConcept C71924100 @default.
• W2765431857 hasConceptScore W2765431857C121608353 @default.
• W2765431857 hasConceptScore W2765431857C126322002 @default.
• W2765431857 hasConceptScore W2765431857C126894567 @default.
• W2765431857 hasConceptScore W2765431857C141071460 @default.
• W2765431857 hasConceptScore W2765431857C143998085 @default.
• W2765431857 hasConceptScore W2765431857C197934379 @default.
• W2765431857 hasConceptScore W2765431857C207103383 @default.
• W2765431857 hasConceptScore W2765431857C2775910329 @default.
• W2765431857 hasConceptScore W2765431857C2780258809 @default.

• next